Form D · Other

Keros Therapeutics, Inc.

Lexington, MA · CIK 0001664710

Offering snapshot reported Mar 12, 2020 · SEC filing

Reported sold
$56M
Offering amount: $56M
Investors reported
20
Form D · investor count
Minimum accepted
$0
Reported outside-investor minimum
First sale
Mar 2, 2020
As reported in this filing

What changed?

Latest filing versus its linked predecessor, where available.

No comparable changes in the displayed metrics.

Filing history

Scroll to see all columns →

FiledFiling typeReported soldChange vs linked filingInvestorsSource
Mar 12, 2020Initial$56,000,057No comparison20SEC filing
Nov 21, 2018Initial$11,499,997No comparison9SEC filing
Nov 13, 2017Amendment$11,000,000$7,666,667vs Apr 29, 20167SEC filing
Aug 18, 2016Amendment$3,666,667$333,334vs Apr 29, 20166SEC filing
Apr 29, 2016Initial$3,333,333No comparison5SEC filing

Offering details

Securities
Equity
Exemptions
06b
Duration over one year
No
Business combination
No
Sales commissions
$0
Finders' fees
$0
Form D file number
021-362700

Source: Form D, filed Mar 12, 2020. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No confirmed ADV fund connection is available for this issuer.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
NameReported role
Zafrira Avnur Director
Nima Farzan Director
Carl Gordon Director
Ohad Hammer Director
Julius Knowles Director
Jenn Lachey Executive
Alon Lazarus Director
Ran Nussbaum Director
Claudia Ordonez Executive
Keith Regnante Executive
Jasbir Seehra Director, Executive

Issuer details

Industry: Other (See others in industry)

Address:
99 Hayden Avenue Building E, Suite 120
Lexington, MA, 02421